All News ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-07-15 EDT			5-day change	1st Jan Change
28,150 ^KRW	-1.05%		-2.43%	+14.43%

07-11	ABL Bio Inc. announced that it has received KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI
07-02	ABL Bio Inc. announced that it expects to receive KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABL Bio Inc. announced that it has received KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	07-10	CI
ABL Bio Inc. announced that it expects to receive KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	07-01	CI
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	06-10	MT
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	03-26	AQ
Biocytogen and ABL Bio enter into a collaboration to jointly develop new dual-antibody ADC drugs	03-26	AQ
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	03-25	CI
ABL Bio Taps into Synaffix ADC Technology	23-09-14	AQ
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors	22-07-22	MT
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	22-01-11	AQ
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	22-01-11	CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting	21-11-12	CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009	21-10-08	CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting	21-10-05	CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody	21-08-04	CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody	21-07-09	CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors	21-04-06	CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors	21-03-30	CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody	20-09-14	CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific	20-06-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News ABL Bio Inc.

Equities

A298380

KR7298380007

All News

Filters